STOCK TITAN
  1. Home
  2. News
  3. FWBI

First Wave BioPharma Inc - FWBI STOCK NEWS

Welcome to our dedicated news page for First Wave BioPharma (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect First Wave BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of First Wave BioPharma's position in the market.

News
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
Rhea-AI Summary
First Wave BioPharma announces agreement with Sanofi to license and repurpose Capeserod for gastrointestinal indications. First Wave will receive an exclusive global license for Capeserod and will assume responsibility for all future clinical development. The agreement includes upfront payment, milestone payments, and royalties on net sales. Sanofi has conducted trials suggesting potential applications for Capeserod in multibillion-dollar markets. First Wave plans to initiate clinical trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.78%
Tags
none
-
News
First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
First Wave BioPharma to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.17%
Tags
conferences
-
News
First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering
Rhea-AI Summary
First Wave BioPharma, Inc. has announced the pricing of a public offering of 3,285,000 shares of its common stock and warrants to purchase up to 6,570,000 shares at a combined public offering price of $0.64 per share. Each share is being sold with two warrants, each to purchase one share. The warrants have an exercise price of $0.64 per share and expire five years after issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
offering
News
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
Rhea-AI Summary
First Wave BioPharma, Inc. announces topline results from Phase 2 SPAN clinical trial of adrulipase for exocrine pancreatic insufficiency in cystic fibrosis patients. The enhanced formulation showed improved safety and tolerability but likely did not meet the primary efficacy endpoint. Additional findings on primary and secondary endpoints to be reported in eight weeks. Plans to pursue an End-of-Phase 2 meeting with FDA for a registrational Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.46%
Tags
clinical trial
-
News
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
clinical trial
News
First Wave BioPharma Strengthens Intellectual Property Estate
Rhea-AI Summary
First Wave BioPharma announces the publication of two patent applications for its enhanced enteric microgranule delivery formulation of adrulipase. The patents cover composition of matter and methods of use claims for the treatment of malabsorption. The company emphasizes the importance of its multilayered IP for its drug technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
none
-
News
First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
conferences
-
News
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.1%
Tags
none
News
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
Rhea-AI Summary
First Wave BioPharma achieves enrollment target in Phase 2 SPAN trial for adrulipase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.1%
Tags
clinical trial
Stock FWBI logo
First Wave BioPharma Inc

Nasdaq:FWBI

FWBI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

FWBI Stock Data

6.72M
1.91M
6.76%
4.07%
2.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Brooklyn

About FWBI

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.